ReposiTrak Balans Gezondheid
Financiële gezondheid criteriumcontroles 6/6
ReposiTrak heeft een totaal eigen vermogen van $50.5M en een totale schuld van $0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk $57.4M en $6.9M. De EBIT ReposiTrak is $7.5M waardoor de rentedekking -5.4 is. Het heeft contanten en kortetermijnbeleggingen van $26.4M.
Belangrijke informatie
0%
Verhouding schuld/eigen vermogen
US$0
Schuld
| Rente dekkingsratio | -5.4x |
| Contant | US$26.41m |
| Aandelen | US$50.49m |
| Totaal verplichtingen | US$6.88m |
| Totaal activa | US$57.38m |
Recente financiële gezondheidsupdates
Recent updates
TRAK: Expanding Food Traceability Adoption And Compliance Wins Will Drive Upside
Analysts have kept their ReposiTrak price target effectively unchanged at approximately $16.00, reflecting only very small tweaks in inputs such as discount rate, revenue growth, profit margin and future P/E assumptions, rather than any shift in their overall view of the stock. What's in the News A wholesale grocery cooperative in the Southern United States became the first wholesaler to reach full supplier to store traceability using ReposiTrak’s Touchless Traceability solution, achieving FSMA 204 compliance without case-level scanning or changes to distribution center workflows (Key Developments).TRAK: Expanding Traceability Network Adoption Will Support Future Upside
Analysts held ReposiTrak's fair value estimate at $16.00 per share while making only very small tweaks to assumptions such as the discount rate and future P/E, reflecting largely unchanged views on the stock's risk and earnings profile. What's in the News ReposiTrak reported that eighteen fresh fruit and vegetable companies have joined the queue for the ReposiTrak Traceability Network to prepare for FDA Key Data Element sharing across their supply chains, covering a wide range of growers and distributors across the United States (Key Developments).TRAK: Expanding Traceability Adoption And Share Repurchases Will Support Future Upside
Analysts have maintained their $16.00 price target on ReposiTrak, linking this steady view to only slight adjustments in discount rate and future P/E assumptions rather than any change in projected growth or profitability. What's in the News ReposiTrak and SPAR Group, Inc.TRAK: Expanding Traceability Adoption And Share Repurchases Will Support Future Upside
Analysts have reaffirmed a $16.00 price target for ReposiTrak, citing only minimal tweaks to underlying assumptions such as discount rate, revenue growth, profit margin and future P/E, which together leave their overall valuation view effectively unchanged. What's in the News A grocery retailer using ReposiTrak Touchless Traceability is reported as the first to achieve end to end traceability under FDA FSMA Section 204, with hundreds of thousands of Key Data Element records generated across shipments, and several more corporate customers nearing similar go live milestones (Key Developments).TRAK: Expanding Traceability Network And Share Buybacks Will Support Future Upside
Analysts have modestly reduced their price target on ReposiTrak to reflect a slightly lower future P/E assumption of 36.44x, while keeping key fair value and growth inputs broadly unchanged. What's in the News A grocery retailer using ReposiTrak Touchless Traceability has achieved end to end FSMA 204 traceability, generating hundreds of thousands of FDA Key Data Element records without case level scanning, with three more corporate customers close to similar go live points (Key Developments).TRAK: Traceability Network Adoption Will Support Higher Future Profitability
Analysts have reduced their price target on ReposiTrak from $29 to $16, citing updated assumptions in their models for slower revenue growth, a lower future P/E multiple, and a higher profit margin profile. What's in the News ReposiTrak reported completing a share repurchase program announced on May 9, 2019, buying back a total of 2,220,026 shares, or 11.63% of the company, for US$14.46 million, including 79,927 shares, or 0.44%, repurchased between October 1, 2025 and December 31, 2025 for US$1.1 million (Key Developments).ReposiTrak: Better Business, Fairer Price, Still Not A Buy
Summary ReposiTrak, Inc. is a micro-cap SaaS firm focused on supply chain compliance, food safety, and traceability for retailers and suppliers. TRAK's revenue grew 10% YoY, driven by recurring subscriptions and expanding services to existing customers, especially as retailer requirements outpace federal mandates. Operating expenses rose 3%, but revenue outpaced costs, supporting a 28% increase in operating income and strong revenue-per-employee metrics. Liquidity remains robust with $28.8M in cash and zero debt, though higher tax rates and rising costs warrant close monitoring if adoption slows. Read the full article on Seeking AlphaInvestors Will Want ReposiTrak's (NYSE:TRAK) Growth In ROCE To Persist
There are a few key trends to look for if we want to identify the next multi-bagger. One common approach is to try and...Subdued Growth No Barrier To ReposiTrak, Inc.'s (NYSE:TRAK) Price
ReposiTrak, Inc.'s ( NYSE:TRAK ) price-to-earnings (or "P/E") ratio of 46.4x might make it look like a strong sell...ReposiTrak's (NYSE:TRAK) Performance Is Even Better Than Its Earnings Suggest
ReposiTrak, Inc. ( NYSE:TRAK ) just reported healthy earnings but the stock price didn't move much. Investors are...Earnings Not Telling The Story For ReposiTrak, Inc. (NYSE:TRAK)
With a price-to-earnings (or "P/E") ratio of 62.3x ReposiTrak, Inc. ( NYSE:TRAK ) may be sending very bearish signals...ReposiTrak, Inc. (NYSE:TRAK) Not Lagging Market On Growth Or Pricing
With a price-to-earnings (or "P/E") ratio of 71.3x ReposiTrak, Inc. ( NYSE:TRAK ) may be sending very bearish signals...
Critical Focus On Traceability Solutions Powers Revenue Growth And Profitability Surge
Emphasis on enhancing traceability solutions and strategic revenue focus predicts significant growth, with aims to improve net margins and year-over-year growth.Track And Trace, But Don't Race: Why ReposiTrak Might Be Overvalued
Summary ReposiTrak shows solid growth potential with traceability services and recurring revenue but is currently overvalued with a high P/E ratio of 62.09x. Despite strong financials and profitability, rising operational expenses and heavy FDA dependency pose significant risks. Expansion into adjacent markets and AI-driven operational efficiencies are promising, but traceability revenue remains a small portion of the business. Given the speculative nature and high valuation, I recommend holding off on investing in ReposiTrak at this price. Read the full article on Seeking AlphaReposiTrak, Inc.'s (NYSE:TRAK) P/E Is Still On The Mark Following 28% Share Price Bounce
ReposiTrak, Inc. ( NYSE:TRAK ) shareholders have had their patience rewarded with a 28% share price jump in the last...ReposiTrak (NYSE:TRAK) Has More To Do To Multiply In Value Going Forward
What are the early trends we should look for to identify a stock that could multiply in value over the long term? One...Why Investors Shouldn't Be Surprised By ReposiTrak, Inc.'s (NYSE:TRAK) 28% Share Price Surge
Despite an already strong run, ReposiTrak, Inc. ( NYSE:TRAK ) shares have been powering on, with a gain of 28% in the...Analyse van de financiële positie
Kortlopende schulden: De korte termijn activa ( $33.1M ) TRAK } overtreffen de korte termijn passiva ( $6.8M ).
Langlopende schulden: De kortetermijnactiva TRAK ( $33.1M ) overtreffen de langetermijnschulden ( $114.9K ).
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: TRAK is schuldenvrij.
Schuld verminderen: TRAK heeft geen schulden vergeleken met 5 jaar geleden, toen de schuld/eigen vermogen-ratio 13.4% was.
Schuldendekking: TRAK heeft geen schulden en hoeft daarom niet gedekt te worden door de operationele kasstroom.
Rentedekking: TRAK heeft geen schulden, dus de dekking van rentebetalingen is geen probleem.
Balans
Ontdek gezonde bedrijven
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/25 15:34 |
| Aandelenkoers aan het einde van de dag | 2026/05/22 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/06/30 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
ReposiTrak, Inc. wordt gevolgd door 4 analisten. 1 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Thomas Forte | D.A. Davidson & Co. |
| Ananda Baruah | Loop Capital Markets |
| Thomas Forte | Maxim Group |